Veraxa Biotech expands FDA-aligned non-animal testing models, aiming to cut animal use in oncology R&D

• Veraxa outlined an ESG-linked shift to FDA-aligned New Approach Methodologies to cut animal testing across its oncology R&D programs.
• Strategy targets faster clinical progress, lower development costs, shorter timelines, reduced reliance on non-human primate toxicology studies.
• Ex vivo NSCLC panel used about 10 mice versus an estimated 200+ for comparable in vivo efficacy work, accelerating preclinical cycles.
• Company positioned the move as aligned with the FDA’s roadmap to phase down animal testing in drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070700OMX_____CNEWS_EN_GNW1001276656_en) on October 07, 2026, and is solely responsible for the information contained therein.